This is a demo store. No orders will be fulfilled.

Ociperlimab (anti-TIGIT) - Primary antibody, specific to TIGIT, >95% (SDS-PAGE&SEC), high purity, Human IgG1, INHIBITOR of T-cell immunoreceptor with Ig and ITIM domains inhibitor, INHIBITOR of T-cell immunoreceptor with Ig and ITIM domains inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab182915
Grouped product items
SKU Size
Availability
Price Qty
Ab182915-100μg
100μg
10
$69.90
Ab182915-1mg
1mg
4
$339.90
Ab182915-5mg
5mg
1
$779.90
Ab182915-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,249.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Ociperlimab (anti-TIGIT) - Primary antibody, specific to TIGIT, >95% (SDS-PAGE&SEC), high purity, Human IgG1, INHIBITOR of T-cell immunoreceptor with Ig and ITIM domains inhibitor
Synonyms DKFZp667A205 antibody | ENSMUSG00000071552 antibody | FLJ39873 antibody | RGD1563191 antibody | T cell immunoreceptor with Ig and ITIM domains antibody | TIGIT antibody | TIGIT_HUMAN antibody | V-set and immunoglobulin domain containing 9 antibody | V-set
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity TIGIT
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type INHIBITOR
Mechanism of action INHIBITOR of T-cell immunoreceptor with Ig and ITIM domains inhibitor
Product Description

Ociperlimab (anti-TIGIT) is a humanized IgG1 anti-TIGIT antibody. Ociperlimab (anti-TIGIT) binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab (anti-TIGIT) blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab (anti-TIGIT) can be used in research of cancer.

Purity

>95% (SDS-PAGE&SEC)

Endotoxin Level

< 1.0EU/mg

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 26.4 kDa (Light Chain) & 52.2 kDa (Heavy Chain), under reducing conditions; 187.7 kDa, under non-reducing conditions.
Purification Method Protein A purified
Purity >95% (SDS-PAGE&SEC)
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 2342597-93-5

Associated Targets(Human)

TIGIT Tbio T-cell immunoreceptor with Ig and ITIM domains (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Ociperlimab (anti-TIGIT) (Ab182915) - ELISA
Immobilized Recombinant Human TIGIT Protein (rp152378) at 1.0 μg/mL can bind Ociperlimab (anti-TIGIT) (Ab182915) with the EC₅₀ of 120.2 ng/mL.​

Ociperlimab (anti-TIGIT) (Ab182915) - SEC
The purity of Ociperlimab (anti-TIGIT) (Ab182915) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number Certificate Type Date Item
ZJ24F0505647 Certificate of Analysis May 15, 2024 Ab182915
ZJ24F0505646 Certificate of Analysis May 15, 2024 Ab182915
ZJ24F0505645 Certificate of Analysis May 15, 2024 Ab182915

Alternative Products

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.